Category: Press Release

2021.03.30

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

2021.03.29

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

2021.03.24

I-Mab to Host 2021 R&D Day

2021.03.19

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

2021.03.11

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

2021.03.10

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

2021.03.03

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

2021.02.25

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin alfa in Pediatric Patients with Growth Hormone Deficiency

2021.02.24

I-Mab Announces Upcoming Participation at March Conferences

2021.02.10

I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors